In November 2019, Kinnov launches pivotal phase 2 trial in alcohol addiction, “Cocktail”.
Kinnov Therapeutics Clinical Project Manager 14 years of experience in clinical research. Previous experience at Parexel, Onxeo, Danone Research, DBV Technologies
KT Business development advisor Sylvain Yon, Ph.D. is the Deputy CEO of Theraclion (www.theraclion.com). In this role, he leads both the research & development efforts of the company and the business expansion on the Asian markets. Sylvain Yon is a
KT Business development advisor Professor in Immunology and Biotechnology at the University of Montpellier (Faculty of Pharmaceutical sciences); has pioneered in France the transfer of innovation by bridging the gap between academic research and industry in the fields of drug
KT clinical project director Ph. D. in Pharmacology and a Medical Doctor and has held a number of key positions in his over 30 year career in the pharmaceutical industry including : Professor at the CHU Pitié-Salpétrière(1971-1997). Manager of the
KT Scientific advisor Research director at INSERM, head of the team « Physiopathology of dependence and relapse » Inserm unit 952/ CNRS UMR7224, Université Pierre et Marie Curie, Paris VI. He is also President of scientific advisory board of MILDT.
KT Preclinical R&D manager 20 years expertise in CNS pharmacology. Founder of Key-Obs.
General Manager Senior international executive in Pharma industry with 30+ years experience in Europe, Middle East/Africa and Asia. Strong drive, able to manage complex situations. Excellent track record in performances, company transformation and customer culture program. Previous managing experience at
Kinnov Therapeutics CEO 20 years expertise in Med Chem. Founder and Manager of Greenpharma Is author of more than 50 scientific publications and 20 patents.
Kinnov Therapeutics was granted 2.5 M€ by European Commission on 1 October 2019 (Horizon 2020 program)